Previous studies have shown that cisplatin combined with TFPI2 enhances apoptosis and antitumor activity in NPC cells, and docetaxel with TFPI2 induces greater apoptosis and invasion inhibition than either treatment alone, highlighting its potential in NPC treatment 34, 35. This evidence concerns the gene TFPI2 and nasopharyngeal carcinoma.